Trials / Completed
CompletedNCT03002077
Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder
An Open-label, Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 617 (actual)
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the long-term safety and tolerability of rapastinel as an adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rapastinel | Rapastinel pre-filled syringes for IV injections. |
Timeline
- Start date
- 2017-02-03
- Primary completion
- 2018-12-06
- Completion
- 2018-12-06
- First posted
- 2016-12-23
- Last updated
- 2020-06-22
- Results posted
- 2020-06-22
Locations
128 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03002077. Inclusion in this directory is not an endorsement.